Largest Biotechnology Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
135.16 B
 0.05 
 1.68 
 0.09 
2AMGN Amgen Inc
91.84 B
 0.10 
 1.78 
 0.18 
3GILD Gilead Sciences
58.99 B
 0.03 
 2.06 
 0.07 
4GMAB Genmab AS
45.81 B
 0.06 
 1.97 
 0.12 
5REGN Regeneron Pharmaceuticals
37.76 B
(0.01)
 3.51 
(0.04)
6HLN Haleon plc
34.31 B
(0.07)
 1.18 
(0.08)
7BIIB Biogen Inc
28.05 B
 0.03 
 1.90 
 0.06 
8VRTX Vertex Pharmaceuticals
22.53 B
(0.03)
 1.95 
(0.06)
9BNTX BioNTech SE
22.53 B
(0.02)
 3.74 
(0.06)
10GRFS Grifols SA ADR
21.41 B
 0.23 
 2.27 
 0.51 
11MRNA Moderna
14.14 B
 0.10 
 3.66 
 0.36 
12UTHR United Therapeutics
7.36 B
 0.02 
 2.40 
 0.04 
13BMRN Biomarin Pharmaceutical
6.99 B
(0.05)
 1.65 
(0.08)
14ARGX argenx NV ADR
6.2 B
(0.02)
 2.30 
(0.06)
15EXAS EXACT Sciences
5.93 B
 0.07 
 2.40 
 0.17 
16ONC BeiGene,
5.92 B
 0.10 
 2.59 
 0.27 
17INCY Incyte
5.44 B
 0.14 
 1.90 
 0.27 
18ROIV Roivant Sciences
5.44 B
 0.05 
 1.91 
 0.09 
19ALNY Alnylam Pharmaceuticals
4.3 B
 0.21 
 2.30 
 0.48 
20GLPG Galapagos NV ADR
4.14 B
 0.21 
 1.77 
 0.37 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.